Baseline characteristics of all subjects and subjects classified by quintiles of MR-proADM
| Characteristics | Total | Quintiles of MR-proADM (nmol/l) | p Value (for trend) | ||||
| 1 | 2 | 3 | 4 | 5 | |||
| N=7903 | N=1580 | N=1581 | N=1581 | N=1581 | N=1580 | ||
| MR-proADM (nmol/l), min–max | 0.01–0.27 | 0.28–0.34 | 0.35–0.40 | 0.41–0.48 | 0.49–2.19 | ||
| MR-proADM (nmol/l) | 0.39±0.14 | 0.21±0.05 | 0.31±0.02 | 0.38±0.02 | 0.44±0.02 | 0.59±0.12 | <0.001 |
| Age (years) | 49±13 | 43±11 | 44±11 | 47±11 | 51±11 | 60±11 | <0.001 |
| Male gender (%) | 49.0 | 37.7 | 50.2 | 54.5 | 53.1 | 49.5 | <0.001 |
| Smoking/quit smoking <1 yr (%) | 38.0 | 33.0 | 36.2 | 39.4 | 41.4 | 40.3 | <0.001 |
| BMI (kg/m2) | 26.1±4.2 | 25.1±3.9 | 25.1±3.8 | 25.6±3.9 | 26.4±4.1 | 28.1±4.6 | <0.001 |
| Systolic BP (mm Hg) | 129±20 | 124±18 | 124±18 | 126±18 | 130±20 | 138±23 | <0.001 |
| Diastolic BP (mm Hg) | 74±10 | 72±9 | 72±9 | 73±9 | 75±10 | 77±10 | <0.001 |
| Heart rate (bpm) | 69±10 | 69±10 | 68±10 | 69±10 | 70±10 | 70±11 | <0.001 |
| Myocardial infarction (%) | 6.5 | 4.4 | 4.3 | 5.0 | 5.4 | 13.4 | <0.001 |
| Stroke (%) | 0.8 | 0.6 | 0.3 | 0.4 | 1.1 | 1.8 | <0.001 |
| Hypertension (%) | 30.9 | 20.7 | 21.4 | 23.7 | 34.8 | 54.2 | <0.001 |
| Hypercholesterolaemia (%) | 26.1 | 17.7 | 20.2 | 24.8 | 30.0 | 37.8 | <0.001 |
| Diabetes mellitus (%) | 3.6 | 1.7 | 1.7 | 2.3 | 3.9 | 8.6 | <0.001 |
| Glucose (mmol/l) | 4.9±1.1 | 4.7±0.9 | 4.7±0.9 | 4.8±1.0 | 4.9±1.1 | 5.3±1.5 | <0.001 |
| Total cholesterol (mmol/l) | 5.6±1.1 | 5.4±1.1 | 5.4±1.1 | 5.6±1.1 | 5.8±1.1 | 6.0±1.1 | <0.001 |
| HDL cholesterol (mmol/l) | 1.33±0.40 | 1.40±0.41 | 1.35±0.40 | 1.33±0.41 | 1.30±0.40 | 1.25±0.37 | <0.001 |
| Triglycerides (mmol/l) | 1.15 (0.84–1.68) | 1.08 (0.78–1.53) | 1.03 (0.76–1.51) | 1.12 (0.82–1.62) | 1.22 (0.87–1.71) | 1.37 (1.02–1.94) | <0.001 |
| C reactive protein (mg/l) | 1.3 (0.6–2.9) | 1.0 (0.4–2.4) | 0.9 (0.4–2.2) | 1.0 (0.5–2.4) | 1.3 (0.6–2.9) | 2.3 (1.1–4.9) | <0.001 |
| NT-proBNP (ng/l) | 37 (17–73) | 34 (16–62) | 29 (13–55) | 32 (14–59) | 38 (17–75) | 62 (31–128) | <0.001 |
| UAE (mg/24 h) | 9.38 (6.37–17.05) | 8.50 (6.09–13.78) | 8.73 (6.19–14.67) | 9.35 (6.39–15.69) | 9.37 (6.43–17.38) | 11.85 (6.94–27.84) | <0.001 |
| Cystatin-C (mg/l) | 0.77 (0.69–0.87) | 0.71 (0.64–0.80) | 0.73 (0.68–0.83) | 0.76 (0.68–0.83) | 0.80 (0.72–0.88) | 0.90 (0.80–1.03) | <0.001 |
| eGFR (ml/min/1.73 m2) | 81±15 | 84±15 | 85±14 | 83±13 | 80±13 | 71±14 | <0.001 |
BMI, body mass index; BP, blood pressure; eGFR, estimated glomerular filtration rate; HDL cholesterol, high-density lipoprotein cholesterol; MR-proADM, mid-regional portion of pro-adrenomedullin; NT-proBNP, N-terminal pro-brain-type natriuretic peptide; UAE, urinary albumin excretion.